Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.
Latest Conference Articles
Advertisement
Final results of the ARMANI trial demonstrated that switch maintenance therapy with ramucirumab plus paclitaxel improved survival in advanced HER2-negative gastric or gastroesophageal junction cancer.
Advertisement
Assisted reproductive techniques may be safe for patients with BRCA-mutated breast cancer, according to an ESMO study.
Compared with epoetin alfa, treatment with luspatercept improved erythroid response rates and the duration of transfusion independence for lower-risk myelodysplastic syndromes.
Bispecific antibodies like teclistamab offer “more potent” treatment than monoclonal antibodies for patients with relapsed or refractory multiple myeloma.
The administration of CAR T-cell therapy in an outpatient setting was deemed feasible and safe for patients with relapsed/refractory non-Hodgkin lymphoma.
Advertisement
An oncology nurse practitioner highlights the benefits of attending conferences like the ASCO Annual Meeting.
Care teams should maintain frequent communication with patients with chronic myeloid leukemia to ensure best outcomes, even between appointments.
Treatment with acalabrutinib and bendamustine/rituximab in the frontline setting improved progression-free survival in older patients with MCL.
The health care team should provide an open forum for patients with chronic myeloid leukemia to discuss how adverse events from treatment affect daily function.
Advertisement
Patients who recently received a chronic myeloid leukemia diagnosis can benefit from initial discussions about treatment, side effects, and study results.
Glofitamab-gxbm plus gemcitabine and oxaliplatin significantly improved survival in relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.
Resources are available to help patients through a chronic myeloid leukemia diagnosis and treatment.
Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.
As most adverse effects of chronic myeloid leukemia treatment are manageable, patients with the disease may be able to continue their normal lifestyle while receiving therapy.
Most patients with lower-risk myelofibrosis, over a 4-year period, experienced disease progression, as demonstrated by the prospective MOST study.
New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.
A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.
Patients with relapsed/refractory multiple myeloma who also had a lower tumor burden were more likely to derive deeper responses to idecabtagene vicleucel.
Patient-provider conversations are vital to promote the best care for chronic myeloid leukemia, a patient advocate said.
Compared with fulvestrant alone, abemaciclib plus fulvestrant improved progression-free survival in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.
Patients with advanced renal cell carcinoma with previous exposure to lenvatinib derived modest benefit with tyrosine kinase inhibitors.
Adding darolutamide to androgen deprivation therapy and docetaxel delayed the progression from metastatic hormone-sensitive prostate cancer to metastatic castration-resistant disease.
Patients with HER2-positive early breast cancer derived similar outcomes whether they received subcutaneous or intravenous pertuzumab and trastuzumab plus chemo.
Patients treated with enfortumab vedotin before sacituzumab govitecan had low objective response rates and median PFS, which may raise questions about this sequencing approach.
Rates of MRD negativity increased with daratumumab plus VRd in newly diagnosed, transplant-eligible multiple myeloma.
Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.
Patients with biochemically recurrent nonmetastatic hormone-sensitive prostate cancer who are responding well to an enzalutamide regimen may be able to stop treatment with an impact to their quality of life.
Patients with recurrent ovarian cancer did not derive a benefit from adding atezolizumab to chemotherapy and bevacizumab.
Tucidinostat plus R-CHOP was safe and effective for previously untreated diffuse large B-cell lymphoma expressing MYC and BCL-2.
Advertisement
Advertisement
